NETRAMARK HOLDINGS INC. Aktie Logo
CA64119M1059
A3D5X9

NETRAMARK HOLDINGS INC. Aktie

Loading quotes...

Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • NetraMark presents NetraAI: AI aims to reduce failures in late-stage trials

    At the H.C. Wainwright conference, NetraMark introduced its NetraAI platform, which is intended to identify small patient subgroups that can determine the success or failure of clinical trials. The company cites FDA recognition at a Critical Path Innovation Meeting, published scientific articles and initial commercial successes, as well as a distribution partnership with Worldwide Clinical Trials. NetraMark reports a pipeline of around 50 active opportunities, a gross margin profile of about 95% and a cash runway of roughly 24 months after a capital raise in early 2026. The stock traded at $0.70 (+7.69%) and is moving near the lower end of its 52-week range. » More on de.investing.com


  • NetraMark hires capital markets expert Kevin Felix as strategic adviser

    NetraMark appointed Kevin Felix as strategic adviser to strengthen relationships with institutional investors and investment banks in Canada and the U.S., as well as its capital markets and corporate strategy. Felix brings more than 25 years of experience in capital markets, asset management and securities law, most recently serving as president of the Investment Office at Global Atlantic. The appointment coincides with the company’s rollout of its commercialization strategy for its AI solution NetraAI in clinical trials. » More on de.investing.com


  • NetraMark wins first AI-analysis contract via CRO partnership

    NetraMark received a contract through a partnership with a CRO to analyze Phase 2 study data in the field of neurodegeneration. The company will use its NetraAI platform to identify model-based subgroups and patterns in treatment response to support patient stratification and study design. It is NetraMark's first contract that did not come directly from a biopharmaceutical company; financial details were not disclosed. NetraMark has a market capitalization of USD 893 million and remained unprofitable over the past 12 months with a net loss of USD 3.9 million. » More on de.investing.com


  • NetraMark awarded contract for AI analysis of phase 2 depression study

    NetraMark has signed a contract with a global biopharma company to analyze patient data from a phase 2 depression study. The firm is using its NetraAI platform to segment multidimensional clinical data, identify patient subpopulations and evaluate treatment-related response patterns. The assignment is intended to yield insights for the sponsor’s future study design; the sponsor was not named and develops therapies for psychiatric and neurological disorders. Financial terms were not disclosed; the stock closed at $27.39 and has gained 36% over the past year. » More on de.investing.com


  • NetraMark raises $3.11 million in first tranche of private placement

    NetraMark raised $3.11 million in the first, non-brokered tranche of a private placement by issuing 3,110,000 units at $1.00 each; each unit consists of one common share and a half warrant. Whole warrants entitle the holder to acquire one additional common share at $1.35 within two years; the issued securities are subject to a four-month hold period ending May 28, 2026. After the transaction 91,778,520 common shares are outstanding, insiders subscribed for 2,060,000 units, and a second tranche of approximately $390,000 is close to closing; proceeds are to be used for working capital and general corporate purposes. » More on de.investing.com

Fundamentals

Metric Value
Market capitalization
€35.39M
Number of shares
92.75M
52-week high/low
€0.81 - €0.31
Dividends No
Beta
1.43
P/E ratio
-
PEG ratio
-
P/B ratio
-
P/S ratio
-

Company profile

Name
NETRAMARK HOLDINGS INC. Aktie
CEO
George Achilleos
🍪

Parqet  uses cookies. Learn more